World Glaucoma Day 2008: uniting to make a difference


The lack of public knowledge about glaucoma surprises me. Although pretty much everybody has heard of it, little is generally known other than the fact that it affects the eye.

Still today we are hearing glaucoma specialists calling upon the medical community to educate their patients and the public about the dangers of glaucoma. Glaucoma-induced blindness is unnecessary and it is largely the lack of knowledge about the disease and the lack of obvious symptoms, which have earned it its title as the "silent blinding disease" or the "sneak thief of sight". In fact, according to a study by Sommer & co-workers in the early 90s, the silent nature of the disease, particularly in the early stages, means that up to 50% of sufferers are unaware that they have glaucoma. This figure could actually reach an astounding 90% in underdeveloped countries.

Taking these factors into account, there is little wonder that glaucoma remains the second leading cause of blindness worldwide, even though ophthalmologists do have good therapies and surgical interventions at their disposal to prevent this needless blindness.

The Ophthalmology Times group has been fortunate enough to be named the official publication of this important event and I am honoured to play a part, albeit a small one, in this commendable initiative. Please look out for coverage of these key activities both on our website (, within our weekly newsletters and in upcoming issues of our magazine. I do hope that you will join me in wishing the co-ordinators of World Glaucoma Day good luck in their efforts to reduce the unnecessary blindness caused by this condition.

Best wishes,

Fedra PavlouEditor

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.